Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

DYN

Dyne Therapeutics Inc

Dec 20 • 04:00PM ET

23.99

Dollar change -0.31
Percentage change -1.28	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: VTI IWM XBI VXF VB VBR IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.56	Insider Own	23.60%	Shs Outstand	101.75M	Perf Week	-6.76%
Market Cap	2.41B	Forward P/E	-	EPS next Y	-3.77	Insider Trans	-9.79%	Shs Float	77.75M	Perf Month	-20.01%
Income	-294.51M	PEG	-	EPS next Q	-0.94	Inst Own	86.84%	Short Float	13.31%	Perf Quarter	-30.72%
Sales	0.00M	P/S	-	EPS this Y	12.22%	Inst Trans	3.49%	Short Ratio	10.49	Perf Half Y	-32.67%
Book/sh	6.93	P/B	3.46	EPS next Y	-8.65%	ROA	-60.47%	Short Interest	10.35M	Perf Year	104.87%
Cash/sh	7.20	P/C	3.33	EPS next 5Y	-	ROE	-68.69%	52W Range	11.66 - 47.45	Perf YTD	80.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-106.26%	ROI	-40.59%	52W High	-49.44%	Beta	1.16
Dividend TTM	-	Quick Ratio	17.02	Sales past 5Y	0.00%	Gross Margin	-	52W Low	105.75%	ATR (14)	1.62
Dividend Ex-Date	-	Current Ratio	17.02	EPS Y/Y TTM	0.90%	Oper. Margin	-	RSI (14)	32.85	Volatility	5.38% 5.55%
Employees	141	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.25	Target Price	50.42
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	2.28%	Payout	-	Rel Volume	1.48	Prev Close	24.30
Sales Surprise	-	EPS Surprise	-34.83%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	987.10K	Price	23.99
SMA20	-13.57%	SMA50	-19.17%	SMA200	-26.60%	Trades		Volume	1,456,217	Change	-1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15
Oct-12-20	Initiated	Stifel	Buy	$29
Oct-12-20	Initiated	Piper Sandler	Overweight	$34
Oct-12-20	Initiated	JP Morgan	Overweight	$27
Oct-12-20	Initiated	Jefferies	Buy	$47

Show Previous Ratings

Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
08:56AM	Loading…
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%
06:31AM	Dyne Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
06:30AM	Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts (GlobeNewswire)
Aug-29-24 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-24 10:52PM	DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
05:10PM	Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-29-24 08:50AM	Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why (Zacks)
12:00PM	Loading…
Jul-18-24 12:00PM	What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now? (Zacks)
Jul-12-24 08:50AM	Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-24-24 07:30AM	Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (GlobeNewswire)
Jun-13-24 04:40PM	Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-30-24 07:30AM	Dyne Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 07:30AM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
May-21-24 08:39PM	Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock (GlobeNewswire) -7.77%
12:27PM	Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies (Zacks)
07:17AM	Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept (MT Newswires)
May-20-24 05:53PM	Why Is Dyne Therapeutics Stock Soaring On Monday? (Benzinga) +27.82%
04:27PM	Dyne Therapeutics Launches $300 Million Share Offering (MT Newswires)
04:07PM	Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again (Investor's Business Daily)
04:01PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
11:22AM	Update: Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
09:40AM	Loading…
09:40AM	HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Mixed Pre-Bell Monday (MT Newswires)
08:02AM	Dyne shares jump on trial data for muscle disease drugs (BioPharma Dive)
07:47AM	Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints (GlobeNewswire)
May-19-24 08:00AM	Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET (GlobeNewswire)
May-04-24 05:31AM	Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections (GuruFocus.com)
May-02-24 11:52PM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:10PM	Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-30-24 07:32AM	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target (MT Newswires)
Mar-27-24 04:05PM	Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer (GlobeNewswire) +6.42%
08:30AM	Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
Mar-25-24 12:28PM	United Airlines, Dyne Therapeutics fall; Lucid Group, Century Aluminum rise, Monday, 3/25/2024 (Associated Press Finance) -7.72%
07:30AM	Dyne Therapeutics Announces CEO Transition (GlobeNewswire)
Mar-13-24 07:30AM	Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-07-24 01:19PM	Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... (GuruFocus.com)
Mar-05-24 10:53AM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.64%
07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-02-24 12:00AM	CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +7.69%
Feb-14-24 04:15PM	Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-01-24 07:30AM	Dyne Therapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-26-24 11:01PM	Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) +18.21%
Jan-22-24 10:14PM	7 Speculative Stocks to Double Your Money THIS Year (InvestorPlace)
Jan-12-24 01:12PM	Hedge Fund and Insider Trading News: Steve Cohen, Crispin Odey, Bill Ackman, Saba Capital Management, Moab Capital Partners, Eisler Capital, Dyne Therapeutics Inc. (DYN), and More (Insider Monkey)
Jan-11-24 04:05PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -5.36%
Jan-05-24 09:02AM	CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) -7.37%
07:30AM	Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-24 10:46PM	Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock (GlobeNewswire) +31.28%
04:37PM	Todays Stock Market Movers: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
12:39PM	These Stocks Are Moving the Most Today: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
Jan-03-24 04:25PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.09%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
08:19AM	Why Is Dyne Therapeutics (DYN) Stock Up 39% Today? (InvestorPlace)
06:30AM	Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE Platform in Developing Therapeutics for Rare Muscle Diseases (GlobeNewswire)
Jan-02-24 04:05PM	Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials (GlobeNewswire)
Nov-13-23 06:59PM	3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition (InvestorPlace) +18.97%
Nov-07-23 07:30AM	Dyne Therapeutics to Present at November Investor Conferences (GlobeNewswire) +14.58%
Oct-31-23 05:36AM	Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials (GuruFocus.com)
01:11AM	The Dyne Therapeutics Inc (DYN) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-30-23 07:30AM	Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones (GlobeNewswire) +10.57%
Sep-28-23 07:30AM	Dyne Therapeutics to Present at October Investor Conferences (GlobeNewswire)
Sep-20-23 04:05PM	Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire) -5.48%
Sep-15-23 01:52PM	Why Shares of Dyne Therapeutics Fell This Week (Motley Fool)
Sep-14-23 01:22PM	Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc (GuruFocus.com)
Sep-05-23 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-03-23 07:30AM	Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-16-23 08:46AM	SMID Caps Are Poised for a Good Run, Says Oppenheimer And These 2 Stocks Fit the Bill With Over 100% Upside (TipRanks) -9.50%
Jun-01-23 07:30AM	Dyne Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 (GlobeNewswire) -7.56%
May-17-23 11:25AM	We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate (Simply Wall St.)
07:30AM	Dyne Therapeutics Preclinical Data Demonstrating FORCE Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting (GlobeNewswire)
May-11-23 07:30AM	Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-03-23 07:35AM	Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-02-23 04:46PM	Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE Platform Delivery to CNS (GlobeNewswire)
Mar-23-23 07:30AM	Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-20-23 07:30AM	Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Mar-07-23 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-02-23 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire) +5.06%
Mar-01-23 09:00AM	How to chart anchored VWAP multiple time frames: Brian Shannon, CMT (Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock (Benzinga) +12.76%
Feb-05-23 05:03AM	TipRanks Perfect 10 List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks (TipRanks)
Jan-19-23 08:23AM	Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics (Zacks)
Jan-18-23 08:49AM	5 Stocks to Buy as the Drug Industry Bets Big on Innovation (Zacks)
Jan-10-23 12:00PM	All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy (Zacks)
Jan-03-23 07:30AM	Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 09:55AM	Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect? (Zacks)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beskrovnaya Oxana	Chief Scientific Officer	Dec 11 '24	Sale	28.12	2,334	65,632	201,685	Dec 11 08:41 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Dec 11 '24	Sale	28.12	1,455	40,915	127,078	Dec 11 08:40 PM
HIGH SUSANNA GATTI	Officer	Dec 11 '24	Proposed Sale	28.33	5,270	149,299		Dec 11 04:20 PM
Beskrovnaya Oxana	Officer	Dec 11 '24	Proposed Sale	28.33	2,334	66,122		Dec 11 04:19 PM
Scalzo Richard William	Officer	Dec 11 '24	Proposed Sale	28.33	1,455	41,220		Dec 11 04:18 PM
Kersten Dirk	Director	Dec 06 '24	Sale	29.34	101,675	2,983,144	5,434,982	Dec 10 04:05 PM
Kersten Dirk	Director	Dec 09 '24	Sale	29.18	34,437	1,004,872	5,400,545	Dec 10 04:05 PM
Kersten Dirk	Director	Dec 04 '24	Sale	29.39	135,039	3,968,796	5,540,463	Dec 06 04:05 PM
Kersten Dirk	Director	Dec 05 '24	Sale	29.05	3,806	110,564	5,536,657	Dec 06 04:05 PM
Kersten Dirk	Director	Dec 02 '24	Sale	29.67	81,201	2,409,294	5,705,234	Dec 04 04:05 PM
Kersten Dirk	Director	Dec 03 '24	Sale	29.05	29,732	863,715	5,675,502	Dec 04 04:05 PM
McNeill Jonathan	Officer	Nov 25 '24	Proposed Sale	29.69	19,987	593,414		Nov 25 04:11 PM
Forbion Capital Fund IV Cooper	Affiliate	Nov 22 '24	Proposed Sale	30.00	62,301	1,869,030		Nov 22 04:06 PM
Incerti Carlo	Director	Nov 18 '24	Option Exercise	8.69	16,500	143,385	16,500	Nov 18 07:42 PM
Incerti Carlo	Director	Nov 18 '24	Sale	28.73	16,500	474,045	0	Nov 18 07:42 PM
Rhodes Jason P	Director	Nov 14 '24	Sale	33.10	782	25,884	15,962	Nov 18 05:31 PM
Incerti Carlo	Director	Nov 18 '24	Proposed Sale	28.00	16,500	462,000		Nov 18 04:40 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Nov 18 '24	Sale	28.20	2,735	77,127	95,833	Nov 18 04:28 PM
Beskrovnaya Oxana	Chief Scientific Officer	Nov 18 '24	Sale	28.20	2,856	80,539	137,519	Nov 18 04:28 PM
Farwell Wildon	Officer	Nov 18 '24	Proposed Sale	28.39	2,515	71,400		Nov 18 04:13 PM
Scalzo Richard William	Officer	Nov 18 '24	Proposed Sale	28.39	2,735	77,646		Nov 18 04:10 PM
Beskrovnaya Oxana	Officer	Nov 18 '24	Proposed Sale	28.39	2,856	81,081		Nov 18 04:06 PM
McNeill Jonathan	Officer	Nov 18 '24	Proposed Sale	28.39	2,658	75,460		Nov 18 04:05 PM
HIGH SUSANNA GATTI	Officer	Nov 18 '24	Proposed Sale	28.39	2,892	82,103		Nov 18 04:04 PM
Kersten Dirk	Director	Nov 13 '24	Sale	35.24	10,803	380,698	62,301	Nov 15 04:05 PM
Kersten Dirk	Director	Nov 14 '24	Sale	32.82	8,929	293,050	5,786,435	Nov 15 04:05 PM
ForDyne B.V.	Affiliate	Nov 14 '24	Proposed Sale	32.83	1,500,000	49,250,000		Nov 14 04:59 PM
Kersten Dirk	Director	Oct 18 '24	Sale	35.16	13,414	471,636	73,225	Oct 22 04:05 PM
Kersten Dirk	Director	Oct 21 '24	Sale	35.06	121	4,242	73,104	Oct 22 04:05 PM
Kersten Dirk	Director	Oct 16 '24	Sale	35.35	23,671	836,770	99,652	Oct 18 04:05 PM
Kersten Dirk	Director	Oct 17 '24	Sale	35.17	13,013	457,667	86,639	Oct 18 04:05 PM
Kersten Dirk	Director	Oct 02 '24	Sale	35.38	21,518	761,307	128,764	Oct 03 04:05 PM
Kersten Dirk	Director	Oct 01 '24	Sale	35.16	8,423	296,153	150,282	Oct 03 04:05 PM
Kersten Dirk	Director	Sep 30 '24	Sale	35.50	30,942	1,098,577	158,705	Oct 01 04:05 PM
Kersten Dirk	Director	Sep 27 '24	Sale	35.00	32	1,120	189,647	Oct 01 04:05 PM
Kersten Dirk	Director	Sep 25 '24	Sale	35.06	2,357	82,636	190,939	Sep 27 04:05 PM
Kersten Dirk	Director	Sep 26 '24	Sale	35.29	1,260	44,465	189,679	Sep 27 04:05 PM
Kersten Dirk	Director	Sep 20 '24	Sale	36.45	79,411	2,894,795	234,127	Sep 24 04:05 PM
Kersten Dirk	Director	Sep 23 '24	Sale	35.32	40,831	1,442,098	193,296	Sep 24 04:05 PM
Kersten Dirk	Director	Sep 19 '24	Sale	36.17	78,739	2,848,283	313,538	Sep 20 04:05 PM
Kersten Dirk	Director	Sep 18 '24	Sale	35.03	1,554	54,437	392,277	Sep 20 04:05 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 18 '24	Sale	34.41	8,976	308,864	131,636	Sep 19 04:52 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Sep 18 '24	Sale	34.55	1,390	48,024	98,568	Sep 19 04:52 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 18 '24	Sale	34.55	2,339	80,812	140,375	Sep 19 04:51 PM
Scalzo Richard William	Officer	Sep 18 '24	Proposed Sale	34.51	1,390	47,964		Sep 18 04:24 PM
Beskrovnaya Oxana	Officer	Sep 18 '24	Proposed Sale	34.51	2,339	80,715		Sep 18 04:23 PM
McNeill Jonathan	Officer	Sep 18 '24	Proposed Sale	34.51	1,870	64,528		Sep 18 04:21 PM
HIGH SUSANNA GATTI	Officer	Sep 18 '24	Proposed Sale	34.41	8,967	308,512		Sep 18 04:20 PM
Kersten Dirk	Director	Sep 17 '24	Sale	35.13	3,272	114,945	393,831	Sep 18 04:05 PM
Kersten Dirk	Director	Sep 16 '24	Sale	35.04	1,320	46,253	397,103	Sep 18 04:05 PM
Farwell Wildon	Officer	Sep 11 '24	Proposed Sale	32.43	2,645	85,777		Sep 11 04:36 PM
HIGH SUSANNA GATTI	Officer	Sep 11 '24	Proposed Sale	32.43	5,270	170,906		Sep 11 04:34 PM
Scalzo Richard William	Officer	Sep 11 '24	Proposed Sale	32.43	1,468	47,607		Sep 11 04:31 PM
Beskrovnaya Oxana	Officer	Sep 11 '24	Proposed Sale	32.43	2,161	70,081		Sep 11 04:28 PM
McNeill Jonathan	Officer	Sep 11 '24	Proposed Sale	32.43	1,823	59,120		Sep 11 04:26 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 11 '24	Sale	31.89	2,161	68,914	142,714	Sep 11 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Sep 11 '24	Sale	31.89	1,468	46,815	99,958	Sep 11 04:13 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 11 '24	Sale	31.89	5,270	168,060	140,612	Sep 11 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Sep 06 '24	Option Exercise	12.56	116,478	1,463,376	227,500	Sep 10 04:05 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Sep 06 '24	Sale	32.15	126,074	4,052,851	101,426	Sep 10 04:05 PM
Kersten Dirk	Director	Sep 05 '24	Sale	35.03	1,577	55,242	398,423	Sep 09 04:05 PM
Scalzo Richard William	Officer	Aug 19 '24	Proposed Sale	33.65	126,073	4,242,356		Sep 06 04:22 PM
McNeill Jonathan	Officer	Sep 05 '24	Proposed Sale	33.61	166,767	5,605,442		Sep 05 04:34 PM
Cox John	CEO & President	Sep 04 '24	Buy	33.04	32,000	1,057,216	8,000	Sep 04 05:42 PM
Kersten Dirk	Director	Aug 30 '24	Sale	45.59	31,300	1,427,063	400,000	Sep 04 04:05 PM
Kersten Dirk	Director	Aug 28 '24	Sale	44.83	77,853	3,490,029	487,708	Aug 30 04:05 PM
Kersten Dirk	Director	Aug 29 '24	Sale	45.31	56,408	2,555,754	431,300	Aug 30 04:05 PM
Kersten Dirk	Director	Aug 26 '24	Sale	45.30	89,497	4,054,408	630,964	Aug 28 04:05 PM
Kersten Dirk	Director	Aug 27 '24	Sale	44.28	65,403	2,896,045	565,561	Aug 28 04:05 PM
Kersten Dirk	Director	Aug 22 '24	Sale	45.82	95,321	4,368,083	805,549	Aug 26 04:05 PM
Kersten Dirk	Director	Aug 23 '24	Sale	46.23	85,088	3,934,005	720,461	Aug 26 04:05 PM
Kersten Dirk	Director	Aug 21 '24	Sale	46.78	135,763	6,350,605	900,870	Aug 22 04:05 PM
Kersten Dirk	Director	Aug 20 '24	Sale	46.35	86,840	4,025,015	1,036,633	Aug 22 04:05 PM
Forbion Capital Fund IV Cooper	Affiliate	Aug 21 '24	Proposed Sale	46.48	1,025,000	47,642,000		Aug 21 04:02 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Aug 19 '24	Sale	45.12	2,752	124,174	111,022	Aug 20 04:28 PM
McNeill Jonathan	Chief Business Officer	Aug 19 '24	Sale	45.12	2,705	122,054	132,106	Aug 20 04:27 PM
Farwell Wildon	Chief Medical Officer	Aug 19 '24	Sale	45.12	2,321	104,727	143,222	Aug 20 04:27 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Aug 19 '24	Sale	45.12	2,910	131,304	145,882	Aug 20 04:26 PM
Beskrovnaya Oxana	Chief Scientific Officer	Aug 19 '24	Sale	45.12	2,636	118,939	144,875	Aug 20 04:26 PM
Kersten Dirk	Director	Aug 19 '24	Sale	45.82	126,032	5,774,365	1,123,473	Aug 20 04:05 PM
Kersten Dirk	Director	Aug 16 '24	Sale	45.14	122,643	5,535,818	1,249,505	Aug 20 04:05 PM
Farwell Wildon	Officer	Aug 19 '24	Proposed Sale	45.12	2,321	104,718		Aug 19 04:13 PM
Scalzo Richard William	Officer	Aug 19 '24	Proposed Sale	45.12	2,752	124,163		Aug 19 04:12 PM
Beskrovnaya Oxana	Officer	Jun 11 '24	Proposed Sale	45.12	2,636	118,930		Aug 19 04:11 PM
McNeill Jonathan	Officer	Aug 19 '24	Proposed Sale	45.12	2,705	122,043		Aug 19 04:10 PM
HIGH SUSANNA GATTI	Officer	Aug 19 '24	Proposed Sale	45.12	2,910	131,292		Aug 19 04:08 PM
Kersten Dirk	Director	Aug 15 '24	Sale	45.37	180,891	8,206,150	1,372,148	Aug 16 04:05 PM
Kersten Dirk	Director	Aug 14 '24	Sale	43.67	100,650	4,395,386	1,553,039	Aug 16 04:05 PM
Kersten Dirk	Director	Aug 13 '24	Sale	42.78	133,985	5,731,742	1,653,689	Aug 14 04:15 PM
Kersten Dirk	Director	Aug 12 '24	Sale	43.19	78,492	3,390,160	1,787,674	Aug 14 04:15 PM
Kersten Dirk	Director	Aug 09 '24	Sale	42.96	92,164	3,959,145	6,232,959	Aug 12 04:05 PM
Kersten Dirk	Director	Aug 08 '24	Sale	42.74	91,670	3,917,946	6,325,123	Aug 12 04:05 PM
Forbion Capital Fund IV Cooper	Affiliate	Aug 08 '24	Proposed Sale	42.64	1,025,000	43,706,000		Aug 08 04:37 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 21 '24	Option Exercise	5.54	29,787	165,020	178,579	Jun 24 08:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 24 '24	Option Exercise	5.54	10,163	56,303	158,955	Jun 24 08:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 21 '24	Sale	35.01	29,787	1,042,843	148,792	Jun 24 08:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 24 '24	Sale	35.33	10,163	359,059	148,792	Jun 24 08:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 12 '24	Option Exercise	5.54	40,000	221,600	188,792	Jun 13 09:45 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 12 '24	Sale	33.36	40,000	1,334,201	148,792	Jun 13 09:45 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jun 11 '24	Sale	31.34	2,136	66,942	147,511	Jun 11 07:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DYN

Dyne Therapeutics Inc

Upgrade your FINVIZ experience